A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer.
about
Targeting Cell Survival Proteins for Cancer Cell DeathT-Type Ca2+ Channel Inhibition Sensitizes Ovarian Cancer to Carboplatin.Improved prediction of PARP inhibitor response and identification of synergizing agents through use of a novel gene expression signature generation algorithmSurvivin family proteins as novel molecular determinants of doxorubicin resistance in organotypic human breast tumors.MicroRNA regulation and therapeutic targeting of survivin in cancer.Small molecule inhibitor YM155-mediated activation of death receptor 5 is crucial for chemotherapy-induced apoptosis in pancreatic carcinoma.The over-expression of survivin enhances the chemotherapeutic efficacy of YM155 in human hepatocellular carcinoma.Influence of survivin-targeted therapy on chemosensitivity in the treatment of acute myeloid leukemia.Targeting Survivin Enhances Chemosensitivity in Retinoblastoma Cells and Orthotopic Tumors.AML sensitivity to YM155 is modulated through AKT and Mcl-1.Inhibition of Survivin with YM155 Induces Durable Tumor Response in Anaplastic Thyroid Cancer.The twisted survivin connection to angiogenesisLung cancer: Biology and treatment options.A combination of YM-155, a small molecule survivin inhibitor, and IL-2 potently suppresses renal cell carcinoma in murine model.Survivin inhibitor YM155 suppresses gastric cancer xenograft growth in mice without affecting normal tissuesProteomics Suggests a Role for APC-Survivin in Response to Somatostatin Analog Treatment of Neuroendocrine Tumors.Inhibition of skeletal growth of human prostate cancer by the combination of docetaxel and BKM1644: an aminobisphosphonate derivative.Death receptor 5 (DR5) and a 5-gene apoptotic biomarker panel with significant differential diagnostic potential in colorectal cancer.MicroRNA-mediated epigenetic targeting of Survivin significantly enhances the antitumor activity of paclitaxel against non-small cell lung cancer.NF-κB suppresses apoptosis and promotes bladder cancer cell proliferation by upregulating survivin expression in vitro and in vivo.Preclinical assesement of survivin and XIAP as prognostic biomarkers and therapeutic targets in gastroenteropancreatic neuroendocrine neoplasia.Small Molecule Survivin Inhibitor YM155 Displays Potent Activity Against Human Osteosarcoma Cells.Antitumor effect of YM155, a novel small-molecule survivin suppressant, via mitochondrial apoptosis in human MFH/UPS.GRIM-19: A master regulator of cytokine induced tumor suppression, metastasis and energy metabolism.Harnessing Solute Carrier Transporters for Precision Oncology.CCR 20th Anniversary commentary: stayin' alive-antiapoptotic proteins and breast cancer.YM155 sensitizes triple-negative breast cancer to membrane-bound TRAIL through p38 MAPK- and CHOP-mediated DR5 upregulation.Survivin: A novel marker and potential therapeutic target for human angiosarcoma.Recent advances in nanomedicine and survivin targeting in brain cancers.Inhibitors of apoptosis: clinical implications in cancer.Honokiol Radiosensitizes Squamous Cell Carcinoma of the Head and Neck by Downregulation of Survivin.YM155 inhibits topoisomerase function.Identification of Inhibitors against Metastasis Protein “Survivin:” In silico Discovery Using Virtual Screening and Molecular Docking Studies.Targeting the proliferative and chemoresistant compartment in chronic lymphocytic leukemia by inhibiting survivin protein.Survivin-Based Treatment Strategies for Squamous Cell Carcinoma.YM155 enhances docetaxel efficacy in ovarian cancer.Therapeutic significance of targeting survivin in cervical cancer and possibility of combination therapy with TRAIL.Survivin as a novel target protein for reducing the proliferation of cancer cells.Adaptation to chronic exposure to sepantronium bromide (YM155), a prototypical survivin suppressant is due to persistent DNA damage-response in breast cancer cellsmiR-203 inhibits ovarian tumor metastasis by targeting BIRC5 and attenuating the TGFβ pathway
P2860
Q26765447-B4C1C305-85B8-466C-8D14-92D52BEB4A58Q30277635-2BCFD774-D96E-4ED0-9334-57C1724506EDQ33731278-17B52423-8A97-46C1-97DC-83EB826E0890Q33827053-0DDF86CB-C66E-4CF0-8606-2B7C44C6228BQ34991312-A597888E-F081-430B-A032-9F6A9CAB6192Q35294613-1F7AD2DF-4E89-483F-A437-F129F6D551C1Q35742449-D67325FC-44E2-41CA-8F9F-CB7355C8371BQ35914683-CCB51C91-5300-4114-9EB9-04A3A5CB38BAQ35981061-61ABD3D5-CDEF-461D-8A31-F71DA11822CBQ35983805-842155DD-1818-4760-8BA8-5388FBD6C7ABQ36070338-BEB5F743-6A98-4643-85CD-1B962A6795B0Q36301932-85A4A55E-C8F5-4AEF-9160-E1F76C6DA303Q36328370-0DB55C17-9F73-46D5-8ED6-190C390F5B0FQ36356265-0D18D511-5569-4AC9-A914-B2443D358CFEQ36916428-BD92F425-141F-4F26-995A-80F405F642E6Q37314269-E42EF862-62EF-4005-9F09-416F83FF81C5Q37317305-B2BCF041-4E00-4BAD-9CC8-3DC1C1570425Q37402581-83092CDA-21A9-4496-9C42-F025FC6F8DB0Q37437269-3580295F-490B-427A-A879-CF3DB6C5E50CQ37615242-03CEA67C-6C19-4A3D-94A3-0967697B1A75Q37702716-AE93B010-188F-455E-9B08-1F462F517E00Q38750224-3BD5ED75-081E-462A-919F-3B76D13E5B20Q38853955-244F06DA-BAB7-44DE-9B05-C07B2CFE3EBAQ38962203-0964D0F1-05B9-4092-9ABA-977449B166AEQ39204754-847598DF-0EB7-46B4-9D1E-581E0A860F30Q43153984-644A9587-AAED-405C-A5EE-C21296D21EB1Q46889307-7AFAB5DE-D3A2-4CD6-8C41-1C97207B46A3Q47134049-77A1EDCE-2D17-498C-8CF7-3906AB204D5EQ47378913-FEAD5D81-7747-4802-8A0F-11467CE920CAQ47607136-02D1242B-110C-4033-9FEC-1C61FB660216Q47694519-ED959E35-8DD9-4FE6-AAE5-0271EAA6A01CQ49218909-781019B5-8DAF-436F-A012-BE21DD036C9BQ50324758-A5962485-1EA7-43B6-8589-B63094B5E086Q51749083-2CC2461F-11EC-409D-BABF-05F9F6477ECFQ51758973-8B5B7007-53CC-40D1-B733-7586E2A381BFQ52595117-F1AAF72F-EBF1-467B-AC98-FA4882F94E68Q52724810-9598344E-3A53-44E9-B75E-CFE37961FD8DQ55006767-D2FA2902-CBDC-429C-A5B7-F07359739DFAQ57493675-06388E89-EA2E-4B10-B71B-074B0CE2CF21Q58706941-7AAE0937-FE0D-4C87-90C1-613623A776D3
P2860
A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 14 July 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A phase I/II study of sepantro ...... ed non-small-cell lung cancer.
@en
A phase I/II study of sepantro ...... ed non-small-cell lung cancer.
@nl
type
label
A phase I/II study of sepantro ...... ed non-small-cell lung cancer.
@en
A phase I/II study of sepantro ...... ed non-small-cell lung cancer.
@nl
prefLabel
A phase I/II study of sepantro ...... ed non-small-cell lung cancer.
@en
A phase I/II study of sepantro ...... ed non-small-cell lung cancer.
@nl
P2093
P2860
P50
P356
P1433
P1476
A phase I/II study of sepantro ...... ced non-small-cell lung cancer
@en
P2093
A Lopez-Chavez
C A Carter
C Van Sant
S M Steinberg
P2860
P304
P356
10.1093/ANNONC/MDT249
P577
2013-07-14T00:00:00Z